News10/01/2022
TrialSpark forms High Line Bio for sprifermin development
Formation Bio, Inc. →TrialSpark announced High Line Bio following acquisition of worldwide rights to sprifermin from Merck KGaA. TrialSpark took responsibility for future development and commercialization of the investigational osteoarthritis program. Merck was to receive an upfront payment, equity in High Line Bio, potential clinical and commercial milestones, and royalties. Full financial terms were not disclosed. The equity relates to High Line Bio, not a demonstrated parent-company holding. At the time, Merck had completed three trials involving more than 800 patients; sprifermin remained an investigational candidate.